Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Adult Considerations in Spinal Muscular Atrophy: Building Clinician and Patient Medical Teams

Premiere Date: Monday, November 14, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, November 14, 2023
Note: Credit Is No Longer Available

Faculty

Claudia A. Chiriboga, MD, MPH, FAAN (Moderator) Professor of Neurology and Pediatrics Division of Pediatric Neurology Columbia University Medical Center New York, NY

Vanessa Battista, DNP, MBA, MS, RN, CPNP-PC  Senior Nursing Director, Palliative Care Dana Farber Cancer Institute Department of Psychosocial Oncology & Palliative Care Pediatric Nurse Practitioner Boston, MA

Tina Duong, PT, PhD  Physical Therapist Director, Clinical Outcomes Research & Development Division of Neuromuscular Medicine Stanford University Stanford, CA

Statement of Need

Adults now make up more than a quarter of patients with spinal muscular atrophy (SMA), a debilitating genetic disease characterized by progressive muscle weakness and atrophy, but advances in research, supportive care, and disease-modifying therapies have largely centered on pediatric populations. Consequently, adults with SMA often face “fragmented” care pathways that are particularly problematic when transitioning from pediatric to adult care.

In this educational webcast, expert faculty will discuss treatment needs of adult patients with SMA and the unique challenges and experiences of those patients transitioning from pediatric to adult care. The webcast will also include insights about how to navigate systems and utilize the most up-to-date and appropriate therapeutic approaches for adult patients with SMA.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate the burden of SMA on adult patients including clinical, quality of life (QoL), and psychological/psychosocial outcomes.
• Develop best practice interdisciplinary strategies to meet the needs of patients with SMA transitioning from pediatric to adult care.
• Integrate appropriate therapeutic approaches to care for adult patients with SMA.

Financial Support

Supported by an educational grant from Genentech, a member of the Roche Group.

Target Audience

Neurologists, neuromuscular specialists, PAs, NPs, physical therapists, and adult patients with SMA.

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats:
Live Activity

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chiriboga reports the following financial relationships:

Advisory Board/Consultant: Genentech, Inc.; Novartis Pharmaceuticals Corporation; PTC Therapeutics; and Roche

Research Support: AveXis, Inc./Novartis Gene Therapies; Biogen; and Roche

Speakers Bureau: Biogen Colombia; Genentech, Inc.; and Roche

Dr. Battista reports the following financial relationships:

Advisory Board: Biogen and Novartis Pharmaceuticals Corporation

Speakers Bureau: Novartis Pharmaceuticals Corporation

Dr. Duong reports the following financial relationships:

Advisory Board: ActiGraph, LLC; Astellas Pharma Inc.; Avidity Biosciences; Biogen; Dyne Therapeutics; Genentech, Inc.; Pfizer Inc.; Roche; Sanofi; Sarepta Therapeutics, Inc.; and Scholar Rock, Inc.

Consultant: Astellas Pharma Inc.; ATOM; Genentech, Inc.; Roche; and TRiNDS

Grants: Biogen and Ionis Pharmaceuticals, Inc.

Research Support: Biogen

Speakers Bureau: Genentech, Inc. and Sarepta Therapeutics, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Thomas Mitchell (planning committee)

Kellie Busby, PharmD (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sandra Caballero, PharmD (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).